We used everolimus (RAD001) to inhibit mTOR, alone or in combination with anti-EGFR drugs gefitinib or cetuximab, on human cancer cell lines sensitive and resistant to EGFR inhibitors, both in ...

In early studies, the mTOR inhibitor everolimus added to endocrine therapy showed antitumor activity. In this phase 3, randomized trial, we compared everolimus and exemestane versus exemestane and ...

We performed a multi-institutional, single-arm, phase II study of RAD001(everolimus), an oral inhibitor of mTOR, in patients who experienced treatment failure on first-line therapy with gemcitabine.

ORLANDO, Fla.—The use of everolimus, a mammalian target of rapamycin (mTOR) inhibitor, is feasible and efficacious for the prevention of graft-versus-host disease (GVHD) in a series of patients ...

Everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is effective in treating tumors harboring alterations in the mTOR pathway. Mechanisms of resistance to everolimus remain ...

To provide further rationale for using the mTOR inhibitor everolimus in MCL, we evaluated mTOR activity in three mantle cell lines Jeko, Mino and Granta by measuring the phosphorylation profile of ...

In cells, rapamycin and other rapalogs such as everolimus suppress geroconversion from quiescence to senescence. Rapamycin inhibits some, but not all, activities of mTOR. Recently we and others ...

Currently, two mTOR inhibitors, temsirolimus and everolimus, are approved for the treatment of patients with advanced renal cell carcinoma (RCC). Clinical trials comparing single-agent ...

In prior studies, hormonal therapy and single-agent treatment with mTOR inhibitors such as everolimus (Afinitor, Novartis) have demonstrated effectiveness in women with metastatic or recurrent ...

Most patients with a nonmalignant form of kidney tumor had significant tumor shrinkage with the mammalian target of rapamycin (mTOR) inhibitor everolimus (Afinitor), a small multicenter clinical ...

A second study looked at everolimus, another mTOR pathway inhibitor, in a slightly older population of ADPKD patients (mean age, 44.5 years). Patients (n = 433) were randomized in a 1:1 manner to ...

We performed a multi-institutional, single-arm, phase II study of RAD001(everolimus), an oral inhibitor of mTOR, in patients who experienced treatment failure on first-line therapy with gemcitabine.